Traveka Wealth LLC Reduces Position in AstraZeneca PLC (NASDAQ:AZN)

Traveka Wealth LLC reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 7.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,720 shares of the company’s stock after selling 491 shares during the quarter. Traveka Wealth LLC’s holdings in AstraZeneca were worth $375,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca in the second quarter valued at approximately $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the third quarter worth approximately $28,000. Groupama Asset Managment increased its holdings in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after purchasing an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in AstraZeneca during the 3rd quarter valued at $45,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN stock opened at $65.73 on Tuesday. The company has a market cap of $203.80 billion, a P/E ratio of 31.45, a PEG ratio of 1.19 and a beta of 0.46. The stock’s 50-day moving average is $66.00 and its 200 day moving average is $74.78. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 EPS. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. Research analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent research reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.